For patients with low-grade residual disease, complete response rate was 70 percent with UGN-101<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 9, 2023 (HealthDay News) — For patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online Nov. 22 in Urologic Oncology<\/em>.<\/p>\n Solomon L. Woldu, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted a retrospective review of all UGN-101 cases from 15 institutions, focusing on practice patterns, efficacy, and adverse effects. A total of 136 renal units treated from 132 patients were included, with most cases being biopsy-proven low-grade UTUC.<\/p>\n The researchers observed considerable variation in practice patterns; antegrade instillation via a percutaneous nephrostomy was the most common administration technique. Sixty-nine percent of patients were disease-free at the time of first endoscopic evaluation when UGN-101 was utilized in the adjuvant setting, while 37 percent were endoscopically clear on the first evaluation with UGN-101 use in the chemoablative setting. In patients with smaller tumor size prior to UGN-101 induction, complete response was higher; a 70 percent complete response was seen in association with low-volume (<1 cm) residual disease. Twenty-seven percent of cases reported use of maintenance doses. New-onset, clinically significant ureteral stenosis had an overall incidence of 23 percent.<\/p>\n “Patients with upper tract urothelial cancers are often left with the choice of lifelong dialysis or untreated cancers,” Woldu said in a statement. “This drug has enormous potential to save them from either of these fates.”<\/p>\n Two authors disclosed financial ties to biopharmaceutical companies, including UroGen Pharma, the manufacturer of UGN-101.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n